toxylact: a02aa05 Magnesium silicate

The first professional lActological database in the word

Magnesium silicate (ATC A02AA05) is an inorganic magnesium compound, formerly used as an oral antacid and currently used mainly as sterile talc (hydrated magnesium silicate) for chemical pleurodesis.

Definition and classification

Magnesium silicate is the magnesium salt of silicic acid, usually expressed as MgSiO3⋅xH2OMgSiO3​⋅xH2 ​O, and is chemically related to talc (hydrated magnesium silicate).
In the ATC system it is classified under A02AA05 – magnesium compounds used as antacids for acid-related disorders.

Pharmaceutical uses

Historically, orally administered magnesium silicate was used as a non‑absorbable antacid to neutralize gastric hydrochloric acid and relieve heartburn, dyspepsia, and related upper gastrointestinal symptoms.
Today, medicinal use as an oral antacid is largely obsolete, but finely powdered sterile talc (hydrated magnesium silicate) remains widely used as a pleural sclerosing agent for pleurodesis in recurrent malignant pleural effusion and spontaneous pneumothorax.

Mechanism of action

As an antacid, magnesium silicate exerts a local neutralizing effect in the stomach: it reacts with gastric hydrochloric acid to form magnesium chloride and silicon dioxide, reducing intragastric acidity and pepsin activity.
As an intrapleural sclerosing agent, sterile talc (hydrated magnesium silicate) induces a local inflammatory response of the pleura, followed by fibroblast proliferation, collagen deposition, and permanent pleural symphysis, which prevents re‑accumulation of air or fluid.

Pharmacokinetics

After oral administration, magnesium silicate is only minimally absorbed because it acts locally in the gastrointestinal lumen and is rapidly converted to poorly absorbed magnesium salts and silicon dioxide.
Systemic bioavailability is therefore considered negligible, and no clinically relevant human pharmacokinetic parameters have been established.

General toxicity profile

Experimental data indicate low acute oral toxicity; reported animal LD50 values exceed 500 mg/kg, and the compound is not considered carcinogenic.
Regulatory evaluations classify magnesium silicate and related silicates as having low systemic toxicity, although inhalational exposure to talc powders can cause pulmonary granulomas and functional impairment, particularly with excessive or chronic exposure.

When used for pleurodesis, sterile talc (hydrated magnesium silicate) is an effective pleural irritant, and expected adverse effects include fever, chest pain, and mild restrictive changes in lung function; serious complications are uncommon when large‑particle, asbestos‑free medical talc is used.

Use during lactation – toxicological risk

Oral antacid doses

Clinical experience with antacids during breastfeeding is extensive, and magnesium salts (including magnesium carbonate, magnesium hydroxide, and magnesium trisilicate) are considered compatible with breastfeeding at usual therapeutic doses.
These magnesium salts are poorly absorbed from the maternal gastrointestinal tract, and any absorbed magnesium appears naturally in breast milk; additional maternal intake is unlikely to meaningfully increase milk levels or pose a systemic risk to the breastfed infant.

Magnesium silicate (A02AA05) behaves similarly as a non‑absorbable antacid with negligible systemic bioavailability, suggesting that oral use at standard doses during lactation carries a low toxicological risk for the nursing infant.
On this basis, short‑term, low‑dose oral use of magnesium silicate for dyspeptic symptoms in breastfeeding women would be expected to be compatible with breastfeeding, provided that maternal renal function is normal and high cumulative magnesium exposure from other sources is avoided.

Parenteral / intrapleural use (pleurodesis)

In pleurodesis, sterile talc (hydrated magnesium silicate) is administered intrapleurally, with the pharmacological effect confined to the pleural cavity and minimal systemic absorption when appropriate medical formulations and doses are used.
Available data show mainly local and transient systemic reactions (fever, pain); maternal serum levels of magnesium and silicate after pleurodesis are not well characterized but are expected to be low relative to oral exposure limits.

Given the very limited systemic exposure and the fact that magnesium is a normal constituent of breast milk, the toxicological risk for the breastfed infant after maternal pleurodesis with medical talc (magnesium silicate) is considered low, especially after the acute post‑procedure period.
However, because robust lactation‑specific pharmacokinetic data are lacking for intrapleural talc, it is prudent to individualize decisions, monitor the infant clinically, and consider temporary interruption of breastfeeding for 12–24 hours in very preterm or medically fragile infants if large doses or repeated procedures are required.

Overall lactation safety statement (for your monograph)

  • Systemic exposure to magnesium silicate from either oral antacid doses or intrapleural pleurodesis is minimal, and magnesium is a physiological component of human milk.
  • Available clinical and regulatory data for related magnesium antacids in breastfeeding women support a low toxicological risk for the breastfed infant when magnesium silicate is used at recommended doses.
  • No specific adverse effects in breastfed infants have been reported in association with maternal use of magnesium silicate or medicinal talc; routine infant monitoring beyond standard clinical observation is not usually required.

A possible concise risk classification text you can embed:

“On the basis of negligible systemic absorption, normal presence of magnesium in breast milk, and reassuring data for other magnesium antacids, magnesium silicate is considered compatible with breastfeeding at usual doses; toxicological risk to the breastfed infant is expected to be low. Caution is advised in premature or medically unstable infants and in cases of maternal renal impairment.”

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.